MYC Regulates a DNA Repair Gene Expression Program in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors:
- James R. EvansJEJames R. Evans
- Jing WangJWJing Wang
- Cinthia N. ReedCRCinthia N. Reed
- Joy H. CreightonJCJoy H. Creighton
- Kaylee B. GarrisonKGKaylee B. Garrison
- Abigail N. RobertsonARAbigail N. Robertson
- Ashley Lira-RiveraALAshley Lira-Rivera
- Diondre’ D. BaisdenDBDiondre’ D. Baisden
- William P. TanseyWTWilliam P. Tansey
- Rafet Al-TobaseiRARafet Al-Tobasei
- Jessica D. LangJLJessica D. Lang
- Qi LiuQLQi Liu
Open Access
Abstract
Background/Objectives: SCCOHT is an aggressive and often fatal cancer that belongs to the ~20% of cancers defined by mutations to subunits of the SWI/SNF chromatin remodeling complex. In SCCOHT, mutations to the SMARCA4 gene, which encodes the SWI/SNF ATPase BRG1, are sufficient to impair SWI/SNF function. This single genetic lesion leads to a cascade of events that promote tumorigenesis, some of which may involve the intersection of SWI/SNF with oncogenic pathways such as those regulated by the MYC oncogene. In SCCOHT tumors and other cancers marked by SWI/SNF subunit mutation, MYC target genes are recurrently activated, pointing to a relationship between SWI/SNF and MYC that has yet to be fully explored. Methods: In this study, we investigate the contribution of MYC to SCCOHT biology by performing a combination of chromatin binding and transcriptome assays in genetically engineered SCCOHT cell lines, with subsequent validation using patient tumor expression data. Results: We find that MYC binds to thousands of active promoters in the BIN-67 SCCOHT cell line and that the depletion of MYC results in a broad range of gene expression changes with a notable effect on the expression of genes related to DNA repair. We uncover an MYC-regulated DNA repair gene expression program in BIN-67 cells that is antagonized by BRG1 reintroduction. Finally, we identify a DNA repair gene signature that is upregulated in SCCOHT tumors and in tumors defined by loss of the SWI/SNF subunit SNF5. Conclusions: Collectively, these data implicate MYC as a robust regulator of DNA repair gene expression in SCCOHT and lay a foundation for future studies focused on interrogating the relationship between BRG1 and MYC.Keywords
Funding Information
- National Cancer Institute of the National Institutes of Health (R03CA273609, R01CA247833)
This publication has 61 references indexed in Scilit:
- Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic typeiScience, 2025
- The histone methyltransferaseEZH2is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic typeThe Journal of Pathology, 2017
- Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancerNature, 2017
- Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental PathwaysCancer Cell, 2016
- Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic typeThe Journal of Pathology, 2015
- A rationale to target the SWI/SNF complex for cancer therapyTrends in Genetics, 2014
- The tumour suppressor and chromatin‐remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancerEMBO Molecular Medicine, 2012
- Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literatureArchives of Gynecology and Obstetrics, 2011
- Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell IdentitiesMolecular Cell, 2010
- Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targetsLaboratory Investigation, 2010